Early-Phase Oral Solid Dose Drug Product Innovation Centre of Excellence

Early-Phase Oral Solid Dose Drug Product Innovation Centre of Excellence
Product Description

CordenPharma’s Drug Product Innovation Centre of Excellence offers early phase formulation development and manufacturing services for Oral Solid Dose (OSD) drug products, including Bioavailability Enhancement technologies. In collaboration with our Solid State Centre of Excellence, we provide integrated API and drug product services, ensuring a continuous feedback loop between identifying the best API form required for a drug product formulation that provides sufficient absorption / solubility, stability, and processability. First-in-Human (FIH) OSD Capabilities Getting a product into FIH clinical Phase I studies in a flexible, fast, and efficient manner is important. CordenPharma offers an initial developability assessment that includes API profiling and technology selection (conventional, bioavailability enhancing) followed by a screening study (excipients, polymers, etc.), phase appropriate formulation development, and prototype preparation. Utilizing the Accelerated Stability Assessment Program (ASAP) for stability, CordenPharma is able to identify the best prototype to manufacture and advance into FIH quickly. Solubility is one of the key attributes of a drug candidate and one of the biggest challenges in drug development. Approximately 70-90% of New Molecular Entities (NMEs) in today’s drug pipeline are poorly soluble, which complicates delivery and results in poor bioavailability. The majority of these NMEs are DCS Class IIa / IIb and IV, which exhibit low bioavailability due to solubility-limited (IIb) absorption, dissolution rate-limited (IIa) absorption, or permeability limitations (IV). Bioavailability enhancement capabilities are available for addressing formulations containing solubility- or permeability-challenged APIs. We have enabling technologies that can solve solubility-induced absorption issues as well as access to a Lipids Excipient portfolio for SEDDS / SMEDDS, Nanocrystals, and Liposomal formulations that can resolve permeability issues.

Corden Pharma International GmbH

  • DE
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Specifications

Corden Pharma International GmbH

  • DE
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO

More Products from Corden Pharma International GmbH (32)

  • Highly Potent & Oncology Technology Platform Brochure

    Product Highly Potent & Oncology Technology Platform Brochure

    One Source for Highly Potent & Oncological Products • Integrated Supply: APIs & Oral / Sterile Drug Products • State-of-the-art facilities able to handle API and Drug Product of the highest potency • Development, clinical trial and commercial manufacturing • Full-service offering in...
  • Injectables Technology Platform Brochure

    Product Injectables Technology Platform Brochure

    Your Expert Partner for Clinical & Commercial Sterile Injectable Drug Product Supply • Wide & balanced range of sterile injectable services, including capability for combining injectable drugs & devices (combination products) • Aseptic & Terminal Sterilization Fill & Finish Tech...
  • Peptides, Lipids & Carbohydrates Technology Platform Brochure

    Product Peptides, Lipids & Carbohydrates Technology Platform Brochure

    Your Expert Partner for Standard & Proprietary Lipids & Carbohydrates • A specialized Lipids offering including custom and standard lipids (Glycero-Phospholipids, Sphingolipids, Phosphocholine, Pegylated, and Cationic Lipids) • Lipids for support of mRNA vaccine production including Phospho...
  • Small Molecules Technology Platform Brochure

    Product Small Molecules Technology Platform Brochure

    Small Molecule Full-Service Partner of Choice from Advanced Intermediates to Drug Products • Integrated network of cGMP facilities across Europe and US • 1,200 m3 of volumetric capacity in 20 L - 28,000 L reactors with various materials of construction • Clinical (Phase I-III) and ongoing comme...
  • CordenPharma Oligonucleotides Platform

    Product CordenPharma Oligonucleotides Platform

    Your Expert Partner for Oligonucleotide APIs - Process Development & Small-scale: scale-up to 10 mmol per run (small-scale equipment can also support early-stage supply) - Scale-up & Small to Medium-scale: scale-up to 100 mmol per run (supported by OligoPilotTM equipment) - Large-Scale Oligonucleotide Pr...
  • CordenPharma's Early-Phase Peptide Centre of Excellence

    Product CordenPharma's Early-Phase Peptide Centre of Excellence

    In addition to the largest worldwide capacity of commercial SPPS peptide production up to batch sizes exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 Metric Tons of Peptide, CordenPharma's multi-pronged approach to becoming the #1 peptide CDMO supplier extends to small-scale capabilities,...
  • Early-Phase Peptide Manufacturing Centre of Excellence

    Product Early-Phase Peptide Manufacturing Centre of Excellence

    In addition to enhanced large-scale peptide manufacturing with the world's largest SPPS facility available, CordenPharma's multi-pronged approach to becoming the #1 peptide CDMO supplier extends to small-scale capabilities, which started with expansions of non-GMP peptide capacity back in Q4 2020. Now Cord...
  • Lipid NanoParticle (LNP) Formulation

    Product Lipid NanoParticle (LNP) Formulation

    Delivering the capabilities pharma needs to support its drug strategies, CordenPharma offers advanced LNP formulation technologies and forward-integrated sterile injectable manufacturing services to create a proven commercialization pathway. We support requirements for Pre-filled Syringes (PFS), Vials, Am...
  • CordenPharma Peptides Platform

    Product CordenPharma Peptides Platform

    Your Expert Partner for Peptide APIs
    • >> Proven track record delivering world class manufacturing services from early stage to commercial supply, including complex products (e.g., Linaclotide, Enfuvirtide, Mifamurtide, Eptifibatide, Glatiramer, GLP analogues). • >> Proprietary...
  • CordenPharma Oligonucleotide Platform

    Product CordenPharma Oligonucleotide Platform

    Your Expert Partner for Oligonucleotide APIs

    • Process Development & Small-scale: scale-up to 10 mmol per run(small-scale equipment can also support early-stage supply)

    • Scale-up & Small to Medium-scale: scale-up to 100 mmol per run(supported by OligoPilotTM equipment)

    • ...
  • CordenPharma Lipids & Carbohydrate Platform

    Product CordenPharma Lipids & Carbohydrate Platform

    Your Expert Partner for Standard & Proprietary Lipids & Carbohydrates
    • >> A specialized Lipids offering including custom and standard lipids (Glycero-Phospholipids, Sphingolipids, Phosphocholine, Pegylated, and Cationic Lipids). • >> Lipids for support of mRNA vaccine ...
  • CordenPharma Injectables Platform

    Product CordenPharma Injectables Platform

    Your Expert Partner for Clinical & Commercial Injectable Drug Product Supply
    • >> Wide & balanced range of injectable services incl. capability for combining injectable drugs and devices (combination products) • >> Aseptic and Terminal Sterilization Fill & Finish Technologies f...

Corden Pharma International GmbH resources (2)